GSK extends Nicorette line
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline launches Nicorette Mini Lozenges in discreet, pocket-size vials to help smokers address cravings and withdrawal symptoms as they try to quit. The firm said April 27 the line extension dissolves up to three times faster than other nicotine replacement lozenges "and can double a smoker's chances of successfully quitting versus placebo." GSK also announced a "Mini Moments" contest on Facebook allowing consumers to share reasons for quitting. The mint lozenges come in 2-mg and 4-mg sizes. A package of 81 retails for a suggested $55.49
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.